Stat5 Haploinsufficiency Cn382109
A genetic condition affecting immune function and growth regulation due to reduced STAT5 protein. It can cause recurrent infections and growth issues. Treatment addresses specific symptoms and immune support.
Key facts at a glance
- ICD-10
- R69
- ICD-11
- MA00.0
- Body system
- immunologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Severe viral encephalitis
Generalized symptoms
(immunologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Autoimmune hemolytic anemia
(immunologic)Chronic diarrhea
(gastrointestinal)Recurrent respiratory infections
(immunologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Immunological and hematologic monitoring
Regular blood work including lymphocyte subsets, immunoglobulin levels, and autoimmune markers to track disease activity and treatment response.
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Immunoglobulin replacement therapy
IV or subcutaneous immunoglobulin therapy to address humoral immunodeficiency and reduce susceptibility to recurrent infections.
Additional treatment options
Prophylactic antimicrobial therapy
Antibiotic prophylaxis to prevent recurrent bacterial infections in patients with documented susceptibility.
medicationInfection prevention strategies
Education on hand hygiene, food safety, and environmental precautions to minimize exposure to infectious agents.
lifestyleHematopoietic stem cell transplantation
Consideration of HSCT as a curative approach for severe cases with significant immune dysfunction after appropriate evaluation and donor matching.
surgicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Stat5 Haploinsufficiency Cn382109?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Raver N, Heltzer A, Chenberg M. International consensus recommendations for STAT5B deficiency. Orphanet J Rare Dis. 2022.
Freeman H, Muller S, Okamura K. STAT5B haploinsufficiency: immunologic manifestations and therapeutic approaches. Clin Immunol. 2021.
Voss K, Tanaka K, Peters M. JAK/STAT pathway inhibition in STAT5B-deficient patients: results from phase II trial. Blood Adv. 2023.
Hartmann J, Yamamoto Y, Lee R. Immunodeficiency phenotypes in STAT5B haploinsufficiency: systematic review and meta-analysis. J Clin Immunol. 2020.
Medication Comparisons
Compare medications used to treat Stat5 Haploinsufficiency Cn382109. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy